FinancingOSE Immunotherapeutics turns to IRIS for €19.3m bridge financingFrench immunotherapy developer OSE Immunotherapeutics has signed a term sheet for a flexible bridge equity financing with IRIS Capital Investment, giving the Nantes- and Paris-based biotech access to … more ➔
Nuclidium AGRadiopharmaceuticalsExtra boost for Nuclidium: financing round reaches €115 millionBasel-based Nuclidium AG has secured an additional tranche for its ongoing Series B financing round, bringing the total to approximately €115 million. The theranostics company is developing copper-based … more ➔
GSKGSK reports 19% functional cure rate for near-approval hepatitis B drugGSK has linked its chronic hepatitis B drug candidate to a 19% functional cure rate across a pair of Phase III trials, clearing the bar it set for clinical relevance. more ➔
clinical dataHansa data supports full approval plan for IdefirixSwedish rare immunology specialist Hansa Biopharma AB has reported positive topline results from a European post-authorisation efficacy study of Idefirix, strengthening its case to convert the kidney … more ➔
artificial intelligenceEx-Palantir execs raise $12M to develop AI operating system at PercepticPerceptic has raised a $12 million (€10.3 million) seed round to advance an AI operating system used by companies including CSL. more ➔
oncologyAdcendo inks MSD supply deal to run ADC-Keytruda combination studyAdcendo has struck a Keytruda supply agreement with MSD, positioning the Danish biotech to study an antibody-drug conjugate (ADC) with the blockbuster checkpoint inhibitor. more ➔
CDC/Janice Haney CarrEli LillyThree in One Go: LimmaTech, Curevo, Vaccine CompanyShopping spree at Eli Lilly? The US pharma giant is acquiring no fewer than three companies, all active in infectious diseases. Among them is Swiss biotech LimmaTech Biologics AG, led by former CureVac … more ➔
obesityEU backs Novo Nordisk’s oral Wegovy for weight managementNovo Nordisk has moved a step closer to bringing an oral version of Wegovy to the European obesity market, after the Committee for Medicinal Products for Human Use (CHMP) recommended approval of once-daily … more ➔
clinical dataOSE’s Tedopi-Keytruda combo clears Phase II ovarian cancer hurdleFrench biotech OSE Immunotherapeutics has reported positive topline Phase II data for its cancer vaccine Tedopi in recurrent ovarian cancer, but the clinical signal is most clearly seen in combination … more ➔
lung cancerDays after J&J update, Nanobiotix pauses trading amid €75M stock offeringNanobiotix has temporarily paused trading of its shares in Europe while it prices the €75 million stock offering it launched in the wake of new data on its Johnson & Johnson-partnered lung cancer prospect. more ➔
Nuclidium AG
CDC/Janice Haney Carr
